Sensei Biotherapeutics (FTH) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Sensei Biotherapeutics (NASDAQ: FTH):

• 6/26/2026 – Sensei Biotherapeutics is now covered by Robert W. Baird. They set an “outperform” rating and a $57.00 price target on the stock.
• 6/22/2026 – Sensei Biotherapeutics is now covered by HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.
• 6/17/2026 – Sensei Biotherapeutics is now covered by Weiss Ratings. They set a “sell (d-)” rating on the stock.
• 6/11/2026 – Sensei Biotherapeutics was upgraded by BTIG Research to “strong-buy”.

Insiders Place Their Bets

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson purchased 9,230 shares of Sensei Biotherapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was purchased at an average price of $24.36 per share, for a total transaction of $224,842.80. Following the transaction, the chief financial officer directly owned 17,413 shares in the company, valued at $424,180.68. This trade represents a 112.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Anand Kiran Parikh bought 2,806 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the purchase, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 20,219 shares of company stock worth $461,379 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.